"10.1371_journal.pone.0054096","plos one","2013-01-14T00:00:00Z","Rebecca Pio; Zhenyu Jia; Veronique T Baron; Dan Mercola; UCI NCI SPECS consortium of the Strategic Partners for the Evaluation of Cancer Signatures, Prostate Cancer","Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, United States of America; Vaccine Research Institute of San Diego, San Diego Science Center, San Diego, California, United States of America","Conceived and designed the experiments: RP DM. Performed the experiments: RP. Analyzed the data: RP ZJ DM VB. Wrote the paper: RP ZJ DM VB.","D. Mercola is a stockholder of Proveri Inc. of San Diego, a biotechnology start-up company developing prostate cancer related tests. Dr. Baron is a consultant for PellFiCure Pharmaceuticals, Inc., a start-up company developing a combination therapy for prostate cancer. There are no marketed products to declare. A pending patent application is: Michael McClelland, Yipeng Wang, Daniel Mercola: Materials and methods for determining diagnosis and prognosis of prostate cancer. September 2011: US 20110236903. Proveri is developing a multiplex immunohistochemistry prostate cancer diagnosis test based on the material of the pending patent. This does not alter the authorsâ€™ adherence to all the PLOS ONE policies on sharing data and materials. All of the human tissue array data cited in this manuscript is available to the public as referenced in the text.","2013","01","Rebecca Pio","RP",5,TRUE,2,1,4,4,TRUE,TRUE,TRUE,1,"5",TRUE
